Radiopharmacological evaluation of 6-deoxy-6-[18F] fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer
M Wuest, BJ Trayner, TN Grant, HS Jans… - Nuclear medicine and …, 2011 - Elsevier
INTRODUCTION: Several clinical studies have shown low or no expression of GLUT1 in
breast cancer patients, which may account for the low clinical specificity and sensitivity of 2-
deoxy-2-[18F] fluoro-d-glucose ([18F] FDG) used in positron emission tomography (PET).
Therefore, it has been proposed that other tumor characteristics such as the high expression
of GLUT2 and GLUT5 in many breast tumors could be used to develop alternative strategies
to detect breast cancer. Here we have studied the in vitro and in vivo radiopharmacological …
breast cancer patients, which may account for the low clinical specificity and sensitivity of 2-
deoxy-2-[18F] fluoro-d-glucose ([18F] FDG) used in positron emission tomography (PET).
Therefore, it has been proposed that other tumor characteristics such as the high expression
of GLUT2 and GLUT5 in many breast tumors could be used to develop alternative strategies
to detect breast cancer. Here we have studied the in vitro and in vivo radiopharmacological …